A year of experience with COVID‐19 in patients with cancer: A nationwide study

Autor: Mina Khosravifar, Sogol Koolaji, Negar Rezaei, Ali Ghanbari, Seyedeh Melika Hashemi, Erfan Ghasemi, Ali Bitaraf, Ozra Tabatabaei‐Malazy, Nazila Rezaei, Sahar Mohammadi Fateh, Arezou Dilmaghani‐Marand, Rosa Haghshenas, Ameneh Kazemi, Erfan Pakatchian, Farzad Kompani, Shirin Djalalinia
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Cancer Reports, Vol 6, Iss 1, Pp n/a-n/a (2023)
Druh dokumentu: article
ISSN: 2573-8348
DOI: 10.1002/cnr2.1678
Popis: Abstract Background Cancer is a major public health problem and comorbidity associated with COVID‐19 infection. According to previous studies, a higher mortality rate of COVID‐19 in cancer patients has been reported. Aims This study was undertaken to determine associated risk factors and epidemiological characteristics of hospitalized COVID‐19 patients with cancer using a nationwide COVID‐19 hospital data registry in Iran for the first time. Methods In this retrospective study, we used a national data registry of hospitalized patients with Severe Acute Respiratory Syndrome (SARS) symptoms and patients with confirmed positive COVID‐19 PCR between 18 February 2020 and 18 November 2020. The patients were classified into two groups patients with/without malignancy. Logistic regression model was utilized to analyze demographic factors, clinical features, comorbidities, and their associations with the disease outcomes. Results In this study, 11 068 and 645 186 in‐patients with SARS symptoms with and without malignancy were included, respectively. About 1.11% of our RT‐PCR‐positive patients had cancer. In patients with malignancy and COVID‐19, older ages than 60 (OR: 1.88, 95% CI: 1.29–2.74, p‐value: .001), male gender (OR: 1.43, 95% CI: 1.16–1.77, p‐value: .001), concomitant chronic pulmonary diseases (CPD) (OR: 1.75, 95% CI: 1.14–2.68, p‐value: .009), and presence of dyspnea (OR; 2.00, 95% CI: 1.60–2.48, p‐value:
Databáze: Directory of Open Access Journals